Saturday 17 October 2026
Export JSPR’s income statement to Excel — free account
Jasper Therapeutics, Inc.
JSPR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.3% and free cash flow grew 55.7%, each against the same quarter a year earlier.
0.48
0.05
−9.43%
Follow JSPR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.62 | 4.98 | 7.19 | 5.91 | 10.95 | 5.16 | 13.82 | — |
Net Debt/EBITDA |
0.35 | 0.96 | 1.28 | 0.76 | 2.32 | 0.96 | 8.90 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.02 | 0.88 | 0.81 | 1.22 | 1.10 | 0.00 | (183.75) | — |
Capex/Depreciation |
0.00 | (0.39) | (0.24) | (0.59) | (6.44) | 0.00 | — | — |
| (230.31%) | (101.73%) | (112.67%) | (71.44%) | (178.18%) | 210.22% | (0.01%) | — | |
| (131.06%) | (81.55%) | (90.00%) | (53.07%) | (52.37%) | (50.65%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2.25%) | — |
Return on Tangible Assets |
(351.79%) | (114.12%) | (81.30%) | (98.56%) | (36.69%) | (182.36%) | 0.14% | — |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(4.03) | (4.33) | (5.01) | (12.73) | (31.69) | 0.00 | (1.47) | — |
Cash per Share |
1.50 | 4.91 | 8.32 | 10.48 | 74.34 | 32.38 | 4.85 | — |
Shareholders Equity per Share |
0.22 | 4.23 | 7.51 | 9.87 | 61.01 | (57.35) | 20.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.22 | 4.23 | 7.51 | 9.87 | 61.01 | (57.35) | 20.00 | — |
Free Cash Flow |
(77.16) | (63.13) | (52.33) | (46.43) | (36.11) | 0.00 | (0.37) | — |
Working Capital |
21.45 | 60.57 | 76.56 | 34.67 | 79.81 | 16.67 | 1.43 | — |
Capital Expenditures |
0.01 | (0.53) | (0.27) | (0.58) | (2.43) | — | — | — |
Net Current Asset Value |
3.02 | 57.59 | 72.49 | 29.36 | 63.70 | (37.80) | (95.15) | — |
| Other line items | ||||||||
Quick Ratio |
2.17 | 4.70 | 7.02 | 5.51 | 10.65 | 5.09 | 10.89 | — |
Depreciation/Fixed assets |
10.35 | 0.73 | 0.41 | 0.27 | 0.10 | 0.03 | — | — |
Cash ROIC |
(234.92%) | (47.36%) | (31.65%) | (62.55%) | (23.41%) | 0.00% | (5.92%) | — |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(4.03) | (4.29) | (4.99) | (12.57) | (29.56) | 0.00 | (1.47) | — |
Capex per Share |
0.00 | (0.04) | (0.03) | (0.16) | (2.13) | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 0.68 | 0.65 | 0.65 | — | — |
Average Payables |
5.12 | 4.09 | 2.96 | 2.84 | 2.67 | 0.76 | 0.76 | — |
Average Assets |
57.84 | 87.40 | 71.63 | 71.01 | 58.51 | 62.53 | 50.85 | — |
Average Common Equity |
32.91 | 70.06 | 57.21 | 52.75 | 17.19 | (15.06) | (15.06) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Columns are period end dates